Updated: Merck buys Prometheus for $10.8B, bringing precision cancer chops to a potential IBD blockbuster
Merck will buy Prometheus Biosciences for $10.8 billion, fueling a red-hot M&A market as the oncology powerhouse looks to bring its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
